Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Rimsza

Showing results (51-60 of 167) with videos related to

Pageof 17
Sort By:
Cancer Biology & Therapy|August 29, 2013
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitorsAna A Tula-Sanchez, Aaron P Havas, Peter J Alonge, et al.
British Journal of Haematology|July 17, 2021
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic featuresJennifer R Chapman, Alyssa C Bouska, Weiwei Zhang, et al.
NAR Cancer|October 23, 2020
Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphomaYing-Zhi Xu, Piroon Jenjaroenpun, Thidathip Wongsurawat, et al.
Virchows Archiv : an International Journal of Pathology|November 27, 2016
Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphomaSamantha Kendrick, Lisa M Rimsza, David W Scott, et al.
British Journal of Haematology|August 7, 2018
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapyHarald Holte, Klaus Beiske, Merrill Boyle, et al.
American Journal of Hematology|December 22, 2017
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806Daniel O Persky, Hongli Li, Lisa M Rimsza, et al.
Haematologica|February 24, 2018
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohortLisa M Rimsza, Hongli Li, Rita M Braziel, et al.
Blood Neoplasia|July 4, 2025
A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myelomaYuan Xiao Zhu, Soumya Dutta, Gregory J Ahmann, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
American Journal of Clinical Pathology|December 28, 2020
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic SyndromeRebecca L King, Brent Tan, Fiona E Craig, et al.
Pageof 17

Showing results (51-60 of 167) with videos related to

Sort By:
Pageof 17
Cancer Biology & Therapy|August 29, 2013
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitorsAna A Tula-Sanchez, Aaron P Havas, Peter J Alonge, et al.
British Journal of Haematology|July 17, 2021
EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic featuresJennifer R Chapman, Alyssa C Bouska, Weiwei Zhang, et al.
NAR Cancer|October 23, 2020
Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphomaYing-Zhi Xu, Piroon Jenjaroenpun, Thidathip Wongsurawat, et al.
Virchows Archiv : an International Journal of Pathology|November 27, 2016
Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphomaSamantha Kendrick, Lisa M Rimsza, David W Scott, et al.
British Journal of Haematology|August 7, 2018
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapyHarald Holte, Klaus Beiske, Merrill Boyle, et al.
American Journal of Hematology|December 22, 2017
A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806Daniel O Persky, Hongli Li, Lisa M Rimsza, et al.
Haematologica|February 24, 2018
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohortLisa M Rimsza, Hongli Li, Rita M Braziel, et al.
Blood Neoplasia|July 4, 2025
A novel cereblon variant with both exon 8 and 10 deletions in newly diagnosed and relapsed multiple myelomaYuan Xiao Zhu, Soumya Dutta, Gregory J Ahmann, et al.
Ejhaem|September 2, 2022
Transcriptional profiles define drug refractory disease in myelomaYuan Xiao Zhu, Laura A Bruins, Xianfeng Chen, et al.
American Journal of Clinical Pathology|December 28, 2020
Reactive Eosinophil Proliferations in Tissue and the Lymphocytic Variant of Hypereosinophilic SyndromeRebecca L King, Brent Tan, Fiona E Craig, et al.
Pageof 17